Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Scientists uncover immune mechanisms driving rare gastrointestinal disorder

A collaborative team led by Dr. Jingnan Li and Dr. Ji Li at Peking Union Medical College Hospital, together with Associate Professor Xiaohuan Guo at Tsinghua University and Academician Ye-Guang Chen at Tsinghua University School of Life Sciences, published a study in Volume 2, article number 28 of the journal Immunity & Inflammation on June 17, 2026.

26 Jun 2026

New gel coating delivers anti-inflammatory antibodies directly to the esophagus

There are few treatment options available for people with disorders of the esophagus. Delivering drugs directly to this part of the body is difficult, so patients are usually treated with systemic drugs, which can have unwanted side effects.

12 Jun 2026

Natural peptide PEPITEM shows promise in reducing arthritic joint swelling

Scientists investigating the naturally occurring immunopeptide PEPITEM have shown reductions in arthritic joint swelling to a degree comparable to the current standard of care, and reduce the inflammatory changes that cause joint damage.

13 Apr 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

AGA issues updated guidance for pharmacologic treatment of moderate-to-severe Crohn's disease

The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the pharmacological management of moderate-to-severe Crohn's disease.

20 Nov 2025

Genetic inflammatory signature defines depression subtypes and treatment response

Researchers led by Prof. Alessandro Serretti at Kore University of Enna have identified a genetic inflammatory signature that defines specific depression subtypes and influences how patients respond to antidepressant medications, according to new peer-reviewed research published today in Genomic Psychiatry.

21 Oct 2025

Understanding immune drift in biologic therapy for inflammatory skin diseases

Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4).

28 Jul 2025

Anti-TNF drugs proven to prevent perianal fistulas in Crohn's Disease

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn's disease.

23 Dec 2024

Update on diagnosis, risk classification and treatment of Kawasaki Disease

Advances in cardiac imaging techniques and risk categorization have led to improvements in diagnosis, initial treatment and long-term management of patients with Kawasaki Disease, according to a new scientific statement published today in the American Heart Association's flagship, peer-reviewed journal Circulation.

14 Nov 2024

Emerging therapies transform autoimmune hepatitis treatment approaches

Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure.

6 Nov 2024

Understanding Crohn's disease through 'mini-gut' models

Cambridge scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease and how it presents in patients.

10 Jun 2024

Study: Early advanced therapy significantly improves Crohn's disease outcomes

A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy to all patients straight after diagnosis can drastically improve outcomes, including by reducing the number of people requiring urgent abdominal surgery for treatment of their disease by ten-fold.

22 Feb 2024

Mood boosters reduce inflammation in IBD by 18%, study finds

New King's College London research reveals that interventions which improve mood can reduce levels of inflammation in people with inflammatory bowel disease by 18 per cent, compared to having no mood intervention.

24 Jan 2024

AGA releases the first comprehensive evidence-based guideline on management of pouchitis

The American Gastroenterological Association (AGA) has released the first comprehensive evidence-based guideline on the management of pouchitis, the most common complication people with ulcerative colitis experience following surgery to remove their colon.

19 Dec 2023

Charting the future of IBD treatment: From immune modulators to microRNA therapies

In a recent study published in the journal eGastroenterology, researchers delved into the latest therapeutic strategies for managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The paper discusses emerging treatments ranging from immune-modulating drugs and biologics to novel approaches like microRNA upregulators and stem cell therapies, highlighting the need for precision medicine in IBD care.

8 Nov 2023

Using TNF inhibitors during pregnancy not associated with worse fetal or obstetric outcomes

According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477).

7 Nov 2023

Novel and emerging therapies offer new hope for patients with inflammatory bowel disease

Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) that affect the gastrointestinal tract.

7 Nov 2023

Lack of direct comparisons prevents assessment of upadacitinib's benefit in Crohn's disease

Like several immunosuppressive biologics, the JAK inhibitor upadacitinib is also approved for the treatment of Crohn's disease. Commissioned by the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated in an early benefit assessment whether the drug offers an added benefit versus the appropriate comparator therapy to patients with moderate to severe active Crohn's disease who have had an inadequate response, lost response or are intolerant to conventional therapy or a biologic agent.

25 Oct 2023